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Adding ribavirin to interferon á-2b for chronic hepatitis C
infection increased virological response and nausea
Reichard O, Norkrans G, Frydén A, et al for the Swedish Study Group. Randomised, double-blind,
placebo-controlled trial of interferon á-2b with and without ribavirin for chronic hepatitis C.
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Question
In patients with chronic hepatitis C virus (HCV) infection, is
the addition of ribavirin to interferon á-2b eVective and safe?
Design
48 week randomised, double blind, placebo controlled trial.
Setting
5 university hospitals in Sweden.
Patients
100 patients (mean age 40 y, 62% men) who had increased
aminotransferase concentrations for >6 months, serum
antibodies to HCV found by polymerase chain reaction
(PCR), and a diagnosis of chronic hepatitis on a liver
biopsy sample in the previous 12 months. Exclusion crite-
ria included previous treatment with interferon á-2b or
ribavirin, decompensated cirrhosis, autoimmune hepatitis,
chronic hepatitis B infection, HIV infection, current intra-
venous drug use, liver disease related to drug use, or preg-
nancy.
Intervention
Patients were allocated to combination therapy (subcutan-
eous interferon á-2b, 3 MU three times/wk, plus ribavirin,
1000 mg daily in 2 divided doses) (n=50) or monotherapy
(subcutaneous interferon á-2b plus a matching placebo)
(n=50) for 24 weeks. Patients who weighed >75 kg
received 1200 mg of ribavirin. 90% of patients completed
24 weeks of treatment.
Main outcome measures
Virological sustained response (absence of HCV RNA on
PCR at weeks 24 and 48). Secondary outcomes were bio-
chemical and histological responses and safety outcomes.
Main results
Analysis was by intention to treat. More patients allocated
to combination therapy than to monotherapy had a
virological sustained response (p=0.047) (table). Combi-
nation therapy led to more patients with nausea (p=0.02)
needing a dose reduction or discontinuing treatment than
did monotherapy (p=0.03) (table). No diVerences existed
between groups for histological improvement.
Conclusion
In patients with chronic hepatitis C infection, the addition
of ribavirin to interferon á-2b led to an increase in
sustained virological response but also to more dose
reductions or treatment withdrawals and nausea.
Sources of funding: Schering-Plough AB, Sweden; Schering-Plough International.
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Commentary
Treatment with á interferon is widely recom-
mended for chronic hepatitis C.1 However,
the clinically relevant outcome of sustained
response—that is, no HCV RNA in serum by
PCR and normalisation of alanine amino-
transferase (ALT) persisting after treatment
for more than 6 months—is found in only
about 15% of patients. Lower response rates
are observed in patients with genotype 1,
those with a high viral load, or cirrhosis at
start of therapy.2 Ribavirin is an oral nucle-
oside analogue that lowers serum ALT in
chronic hepatitis C but its eVect on HCV rep-
lication is minimal.
Reichard et al carried out a large, double
blind, randomised controlled trial to assess
the eYcacy and safety of combination
therapy with interferon and ribavirin. One
hundred consecutive patients without previ-
ous treatment with interferon or ribavirin
entered the trial and received either á
interferon 3 MU three times weekly plus pla-
cebo daily, or interferon plus ribavirin 1–1.2 g
daily for 24 weeks. Follow up lasted for
another 24 weeks.
Significantly more patients on combina-
tion therapy (16/50) than on interferon
monotherapy (6/50) needed a reduction in
dose or discontinued treatment; depression,
nausea and a decrease in haemoglobin were
more common in the combination therapy
group. A sustained response was seen in 18
(36%) patients on combination and in 9
(18%) on interferon monotherapy (p<0.05).
Subgroup analysis indicated particularly en-
hanced eYcacy of combination therapy in
patients with a high viral load (>8 MEq/ml
by bDNA, Chiron), whereas no eVect could
be shown in patients with genotype 1b.
This relatively large trial was designed and
executed according to modern standards, and
virological assays were of high quality. How-
ever, the number of patients inthe study was
too small to allow subgroup analysis with con-
fidence.
The potential clinical impact of the Swedish
findings is that combination of interferon with
ribavirin will be regarded as the treatment of
choice for patients with chronic hepatitis C
and an indication for antiviral treatment.
However, the greater number of side eVects
and the considerably higher cost of combina-
tion therapy compared with interferon mono-
therapy will mean that this treatment will
probably not be universally applied. Interferon
monotherapy will suYce for 10–20% of
patients, and additional subgroup analysis is
needed to identify those individuals. Further-
more, many patients do not respond to combi-
nation treatment, which should be suspended
if HCV RNA is detected after 12 weeks. Such
a cost eVective strategy, coupled with the now
appreciable chance to eradicate the virus as
suggested by long term follow up studies,3
should widen the application of treatment in
chronic hepatitis C.
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Interferon á-2b plus ribavirin (combination therapy) v interferon á-2b
alone (monotherapy) at 48 weeks in chronic hepatitis C virus infection*
Outcome
Combination
therapy
Mono-
therapy RBI (95% CI) NNT (CI)
Virological response 36% 18% 100% (2 to 302) 6 (3 to 193)
Outcomes Combination
therapy
Mono-
therapy
RRI (CI) NNH (CI)
Dose reduction or
treatment
withdrawal
32% 12% 167% (19 to 520) 5 (3 to 27)
Nausea 34% 12% 183% (27 to 555) 5 (3 to 18)
*RBI=proportional increase in rates of good outcomes between combination
therapy and monotherapy groups; NNT=number of patients who must receive
combination therapy to achieve 1 additional good outcome; RRI=proportional
increase in rates of bad outcomes between combination therapy and
monotherapy groups; NNH=number of patients who, if they received combina-
tion therapy, would lead to 1 additional person being harmed.
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